Tag: age-related macular degeneration market

Posted on by

Age-Related Macular Degeneration Market, Forecast Report 2028

According to Renub Research latest report, “Age-Related Macular Degeneration (AMD) Market, Global Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis” Age-Related Macular Degeneration (AMD) Market is estimated to grow at a CAGR of 8.5% by 2028. Age-related Macular Degeneration is a disorder that causes a steady disintegration of cells in the center of the retina (AMD). It is widespread, and it causes a person to lose central vision. It is the major cause of vision loss in adults aged 50 and over. The wearing down of the macula and the development of the disease are classified as dry and moist. Both kinds are hazardous and need medical attention. Furthermore, the growing needs for therapy among the elderly increases the pote       ntial market for age-related macular degeneration. Age-related Macular Degeneration Industry was US$ 8.62 Billion in 2022.

 

Expert Insights: Ask Analyst or Download Full Report with TOC & Figures: https://www.renub.com/age-related-macular-degeneration-market-p.php

According to the WHO, in 2020, around 196 million people were suffering from age-related macular degeneration globally, including over 10.4 million moderate-to-severe vision impairment cases. The growth of the AMD market is primarily due to the increasing cases of age-related eye diseases, the rising elderly population, and the surge in investments in R&D activities. Moreover, the market grew due to the rise in the prevalence of this condition, the introduction of innovative treatments, a robust product pipeline, and advancements in gene therapies.

 

An Increase in Pipeline Drugs for Dry AMD shall aid its Market Growth

Dry AMD accounts for 85-90% of all instances of macular degeneration. Vitamin formulations are now the sole therapeutic therapy for dry macular degeneration. Furthermore, numerous novel therapeutic options for its treatment, including Zimura, Luminate, and intravitrealpegcetacoplan, are now being evaluated in the medical community.

 

The surge in the Dry Age-related Macular Degeneration (AMD) market is due to the growing older population and increasing prevalence of age-related macular degeneration, and the introduction of novel treatment methods for dry AMD combined with the increasing number of clinical trials focused on dry AMD. In addition, other factors, like increasing healthcare expenditure, will likely help the market grow.

Beovu will grow at the Fastest Rate over the Forecast period due to Patent Protection

The patent for EYLEA expires in 2023 in the United States and in 2025 in Europe, depending on the patent category. As a result, this aspect will contribute to the increase in demand for Beovu. Furthermore, factors such as improved drying effectiveness and success in treating severe cases of wet AMD will contribute to the market’s expansioBecause of its enormous market penetration, the Eylea category dominates. The FDA approved the intravitreal injection of aflibercept for Eylea in 2011. It prevents VEGF from functioning in wet AMD. As a result, it is used to treat diabetic macular edoema, wet AMD, and macular edoema.

 

Request a free sample copy of the report:  https://www.renub.com/request-sample-page.php?gturl=age-related-macular-degeneration-market-p.php

 

Hospitals are the main and Dominating Channel for Distribution

As per the Royal National Institute of Blind People (RNIB), around 26.5 Million people in 2021 were at high risk of developing this condition. Most patients’ treatment is through drugs, such as Eylea, Lucentis, and Beovu, administered intravenously in hospitals under the supervision of competent specialists. Thus, the rising demand for AMD treatment raises the number of hospital visits, fuelling the market of the hospital category.

 

 North America is the Industry leader due to the constant rise in the Geriatric Population

North America has supremacy over the market share and will sustain its dominance in the next few years. Some significant components driving the regional market include the increasing burden of the older population, the upsurge in the prevalence of this disease, the presence of influential market players, and the growing research and development activities in the region. Moreover, advantageous government initiatives, increased research partnerships, recent product launches, and a rise in cases of AMD will boost the regional market’s growth. For instance, according to the American Academy of Ophthalmology, around 15 million North Americans live with AMD.

 

Competitive Landscape:

Prominent companies competing currently in the Age-related Macular Degeneration Market Are F. Hoffman – La Roche Ltd., Bayer AG, Abbvie, GSK Plc., Novartis AG, Regeneron Pharmaceuticals, Bausch Health Companies, and Alimera Sciences Inc.

 

Market Summary:

  • Type – The Report covers Age-related Macular Degeneration (AMD) Market, by type in 2 viewpoints (Wet AMD, and Dry AMD).
  • Product – By Product, the Age-related Macular Degeneration (AMD) Market, breakup in 4 viewpoints (Eylea, Lucentis, Beovu, and Others).
  • Distribution Channel – Renub Research report covers by distribution channel in 3 viewpoints (Hospital Pharmacy, Specialty Pharmacy, and Online Pharmacy).
  • Region – The Age-related Macular Degeneration (AMD) Market by region breakup in 5 viewpoints (North America, Europe, Asia-Pacific, Latin America, and Middle-East and Africa).
  • Key Players- All the major players have been covered from 3 Viewpoints (Overview, Recent Developments, and Revenue) F. Hoffman – La Roche Ltd., Bayer AG, Abbvie, GSK Plc., Novartis AG, Regeneron Pharmaceuticals, Bausch Health Companies, and Alimera Sciences Inc.

 

About the Company:

Renub Research is a Market Research and Information Analysis company with more than 14 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 7000 syndicated reports and worked on more than 500 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets.

 

Media Contact:

Company Name: Renub Research

Contact Person: Rajat Gupta, Marketing Manager

Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)

Address: 225 Kristie Ln, Roswell, GA 30076

Email: info@renub.com

LinkedIn: https://in.linkedin.com/company/renub-research

Thank You https://3dphysioireland.com/

Posted on by

Age-Related Macular Degeneration Market Trends | Forecast Report

Renub Research has recently published a report titled” Age-Related Macular Degeneration Market Size, Forecast 2023-2028, Global Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis” providing a comprehensive analysis of the industry that includes market share insights. In addition, the report comprises competitor and regional research and contemporary extension in the Age-Related Macular Degeneration (AMD) Market. Age-Related Macular Degeneration (AMD) Market is estimated to reach US$ 14.06 Billion by 2028.

 

Expert Insights: Ask Analyst or Download Full Report with TOC & Figures: https://www.renub.com/age-related-macular-degeneration-market-p.php

 

The Age-Related Macular Degeneration market is experiencing notable expansion in recent decade. AMD, a chronic eye condition affecting the retina’s central region, progressively impairs vision. The surging prevalence of AMD, particularly among the elderly demographic, constitutes a key growth catalyst. As the global population ages, AMD incidence is projected to escalate, generating higher demand for efficacious treatment options. Technological advancements in diagnostics and therapies have also fueled the market’s growth. Advanced imaging techniques and innovative treatments like anti-vascular endothelial growth factor (VEGF) drugs have revolutionized AMD management, facilitating early detection, precise monitoring, and targeted interventions, ultimately enhancing patient outcomes. Increased awareness regarding AMD and the significance of routine eye examinations have led to higher diagnosis rates.

 

Educational campaigns and initiatives undertaken by healthcare organizations and advocacy groups have significantly raised awareness, enabling early intervention and timely management of AMD. Government support and favourable reimbursement policies for AMD treatments have further strengthened the market. Accessible insurance coverage for diagnostic tests and therapies has improved patient access to effective treatments, further propelling market growth. Given the rising AMD prevalence, technological advancements, growing awareness, and supportive healthcare policies, the Age-Related Macular Degeneration market is positioned for substantial expansion.

 

The introduction of new and effective treatment options for dry AMD is anticipated to drive market growth

 

The market growth of dry age-related macular degeneration (AMD) is expected to be supported by an increase in pipeline drugs targeting this condition. Dry AMD, a progressive eye disease that causes the deterioration of the macula, is the most common form of AMD. Currently, there are limited treatment options available for dry AMD, and the development of novel drugs holds significant potential for addressing this unmet medical need.

 

The emergence of pipeline drugs specifically designed to target dry AMD presents an encouraging outlook for the market. These drugs aim to address the underlying mechanisms and pathways involved in the progression of dry AMD, such as inflammation, oxidative stress, and the accumulation of drusen. By targeting these key factors, these pipeline drugs have the potential to slow down or halt the progression of the disease, preserving vision and improving patient outcomes.

 

Type – Age-Related Macular Degeneration Market breakup from 2 Viewpoints:

 

  1. Wet AMD
  2. Dry AMD

 

Patent protection offers a favourable environment for sustained growth in the forecast period, positioning Beovu as a key player in the market for wet AMD treatments.

 

Beovu is expected to exhibit the highest growth rate during the forecast period primarily due to its patent protection. Beovu is a medication used for the treatment of various retinal diseases, including wet age-related macular degeneration (AMD). Patent protection grants exclusivity to the manufacturer, preventing generic competitors from entering the market and offering alternative versions of the drug. With its patent protection, Beovu enjoys a competitive advantage, allowing it to maintain a strong market position and capture a significant share. This exclusivity provides the manufacturer with a certain level of market control, enabling them to set pricing strategies and maximize profitability.

The anticipated growth of Beovu can be attributed to the sustained demand for effective treatments for wet AMD and other retinal diseases. As Beovu demonstrates favourable clinical outcomes and gains recognition within the medical community, it is expected to witness increased adoption by healthcare professionals and patients alike.

 

Product – Age-Related Macular DegenerationMarket breakup from 4 Viewpoints

 

  1. Eylea
  2. Lucentis
  3. Beovu
  4. Others

 

Indispensability of hospitals in the AMD treatment market stems from their comprehensive services, strategic partnerships, and direct patient access, which are vital for achieving market success

 

Hospitals play a vital role as the primary and dominant channel for the distribution of healthcare products, including treatments for age-related macular degeneration. Their comprehensive infrastructure and facilities, along with established partnerships with pharmaceutical companies, enable hospitals to efficiently distribute specialized medications and therapies for AMD. Additionally, hospitals serve as referral centers for ophthalmologists and retina specialists, providing direct access to the target patient population. While hospitals dominate the distribution channel, other channels like specialty clinics and retail pharmacies may also contribute depending on regional market dynamics and healthcare infrastructure.

 

Distribution Chanel – Age-Related Macular Degeneration Market breakup from 3 viewpoints:

 

  1. Hospital Pharmacy
  2. Specialty Pharmacy
  3. Online Pharmacy

 

Growing elderly population and a robust healthcare ecosystem positions North America at the forefront of the AMD industry

 

North America has established itself as the industry leader, primarily due to the continuous growth of the geriatric population. With an aging demographic, the region faces a higher prevalence of age-related conditions and diseases, including age-related macular degeneration. This demographic trend creates a significant market demand for AMD treatments and related healthcare services. Additionally, North America boasts advanced healthcare infrastructure, research facilities, and a strong pharmaceutical industry, enabling it to drive innovation and develop cutting-edge therapies for AMD.

 

Request a free sample copy of the report:  https://www.renub.com/request-sample-page.php?gturl=age-related-macular-degeneration-market-p.php

 

Region – Age-Related Macular Degeneration Market breakup of 5 Regions

 

  1. North America
  2. Europe
  3. Asia Pacific
  4. Latin America
  5. Middle East and Africa

 

Competitive Landscape

 

The Age-related Macular Degeneration market is witnessing strong competition among prominent companies, including F. Hoffman – La Roche Ltd., Bayer AG, Abbvie, GSK Plc., Novartis AG, Regeneron Pharmaceuticals, Bausch Health Companies, and Alimera Sciences. These companies have established themselves as key players in the market, offering innovative treatments and therapies for AMD. Their research and development efforts, strategic collaborations, and extensive product portfolios contribute to their competitive advantage. By continuously striving to develop new and improved solutions, these companies aim to meet the growing demand for effective AMD treatments and enhance patient outcomes.

 

The company has been covered from 3 Viewpoints:

 

  • Overview
  • Recent Development
  • Revenue

 

Company Analysis:

 

  1. F. Hoffman – La Roche Ltd.
  2. Bayer AG
  3. Abbvie
  4. GSK Plc.,
  5. Novartis AG,
  6. Regeneron Pharmaceuticals
  7. Bausch Health Companies
  8. Alimera Sciences Inc

 

Browse Related Report:

Telemedicine Market: https://www.renub.com/telemedicine-market-p.php

Viscosupplementation Market: https://www.renub.com/viscosupplementation-market-p.php

Coronary Artery Disease (CAD) Market : https://www.renub.com/coronary-artery-disease-market-p.php

Prostate Cancer Diagnostics Market : https://www.renub.com/prostate-cancer-diagnostics-market-p.php

 

About the Company: 

Renub Research is a Market Research and Information Analysis company with more than 14 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 7000 syndicated reports and worked on more than 500 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets.

 

Media Contact:

Company Name: Renub Research

Contact Person: Rajat Gupta, Marketing Manager

Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)

Address: 225 Kristie Ln, Roswell, GA 30076

Email: info@renub.com

LinkedIn: https://in.linkedin.com/company/renub-research